US Injectable Drug Delivery Market to Reach $465.15 Billion by 2031

Biologics innovation, long-acting injectables, and the shift to home-based care driving rapid market growth

Feb. 14, 2026 at 4:31am

Got story updates? Submit your updates here. ›

The US injectable drug delivery market is projected to grow from $309.90 billion in 2026 to $465.15 billion by 2031, advancing at a CAGR of 8.5%. Valued at $285.81 billion in 2025, the market is being reshaped by biologics innovation, long-acting injectables, and the accelerating shift toward patient-centric, home-based care models.

Why it matters

The expansion of biologics and specialty therapeutics pipelines is fundamentally altering treatment paradigms across chronic and complex diseases. As monoclonal antibodies, peptides, and long-acting injectables gain clinical traction, demand for advanced injectable drug delivery systems continues to rise. Simultaneously, healthcare systems are prioritizing home-based treatment and remote monitoring to reduce hospital burden and optimize cost structures, accelerating the adoption of self-injection systems.

The details

Companies are responding through AI-enabled formulation design, automation in fill-finish operations, and smart, connected injection devices that support real-time monitoring and adherence tracking. Integrated drug–device development models are further enhancing speed-to-market and commercial scalability. Strategic collaborations among pharmaceutical companies, device manufacturers, and CDMOs are strengthening supply chains, improving delivery efficiency, and enabling next-generation injectable solutions designed for both clinical and home settings.

  • The US injectable drug delivery market is projected to grow from $309.90 billion in 2026 to $465.15 billion by 2031.
  • The market was valued at $285.81 billion in 2025.

The players

Johnson & Johnson Services, Inc.

A multinational corporation that develops medical devices, pharmaceutical, and consumer packaged goods.

Pfizer Inc.

A multinational pharmaceutical and biotechnology corporation that develops and produces medicines and vaccines.

BD

A medical technology company that manufactures and sells medical devices, instrument systems, and reagents.

Ypsomed

A Swiss medical device company that specializes in the development and manufacture of injection and infusion systems.

Got photos? Submit your photos here. ›

The takeaway

The US injectable drug delivery market is undergoing a transformative shift driven by the rise of biologics, long-acting injectables, and the growing demand for patient-centric, home-based care models. Companies that invest in advanced formulation science, scalable manufacturing, connected injection technologies, and integrated drug-device platforms will be well-positioned to capture long-term value in this rapidly evolving $465 billion market.